Citicoline (Ceraxon) in acute stroke: assessment of clinical efficacy and effects on cerebral perfusion

Cover Page

Cite item

Full Text


Novel neuroimaging techniques provide quantitative assessment of cerebral perfusion in acute stroke and reveal the heterogeneity of ischemic zone. Neuroprotective agents play major role in the treatment of acute stroke as they are intended to restore functioning of potentially viable tissue. This prospective open-label study included 50 patients (mean age 60.9 years) with acute hemispheric stroke within the first 24 hours of symptoms onset. Patients were divided into 2 arms (25 patients in each arm) to receive standard of care (control arm) or standard of care plus citicoline (Ceraxon) 1 g b.i.d. as I.V. injection for 10 days. Clinical symptoms were assessed with NIHSS; neuroimaging included DWI to confirm ischemic lesion and perfusion CT to assess cerebral perfusion. Patients in both arms demonstrated significant clinical improvement on Day 10 with no significant difference between treatment arms (mean NIHSS score was 9.4 in control arm and 8.4 in Ceraxon arm, p=0.87). Perfusion CT on admission showed perfusion deficit in all patients. Mismatch regions on perfusion CT compared to DWI indicating potentially viable tissue (“penumbra”) were found in 75% of patients in control arm and in 69% of patients in Ceraxon arm. No difference between perfusion parameters in the “core” vs. “penumbra” on initial imaging was shown. On Day 10 there were no changes of cerebral perfusion values in the “core” regions, while in “penumbra” in Ceraxon arm CBF increased significantly CBF (p=0.013) with no significant differences vs. intact hemisphere, that is consistent with cerebral perfusion improvement. Thus, treatment with Ceraxon in the first 10 days of acute stroke may result in improvement of cerebral perfusion in the potentially viable tissue.


About the authors

Michail A. Piradov

Research Center of Neurology

ORCID iD: 0000-0002-6338-0392

D. Sci. (Med.), Professor, Academician of the Russian Academy of Sciences, Director

Russian Federation, 125367, Russia, Moscow, Volokolamskoye shosse, 80

Dmitry V. Sergeev

Research Center of Neurology

Author for correspondence.
Russian Federation, Moscow

Marina V. Krotenkova

Research Center of Neurology

ORCID iD: 0000-0003-3820-4554

D. Sci. (Med.), Head, Radiology department

Russian Federation, 125367, Russia, Moscow, Volokolamskoye shosse, 80


  1. Инсульт: диагностика, лечение, профилактика. Под ред. З.А. Суслиной, М.А. Пирадова. М.: МЕДпресс-информ, 2008.
  2. Корниенко В.Н., Пронин И.Н., Пьяных И.С., Фадеева Л.М. Исследование тканевой перфузии головного мозга методом компьютерной томографии. Медицинская визуализация. 2007; 2: 70–81.
  3. Сергеев Д.В., Кротенкова М.В., Пирадов М.А. Мозговой крово- ток в острейшем периоде полушарного ишемического инсульта: клинический и КТ-перфузионный анализ. Анналы клин. и эксперим. неврологии, 2009; 3 (4): 19–28.
  4. Adibhatla R.M., Hatcher J.F. Citicoline mechanisms and clinical efficacy in cerebral ischemia. J Neurosci Res 2002; 70: 133–139.
  5. Brott T.G., Adams H.P., Olinger C.P. et al. Measurements of acute cerebral infarction: a clinical examination scale. Stroke 1989; 20 (7): 864–870.
  6. Davalos A., Castillo J., Álvarez-Sabín J. et al. Oral Citicoline in Acute Ischemic Stroke: An Individual Patient Data Pooling Analysis of Clinical Trials. Stroke 2002; 33: 2850–2857.
  7. Davalos A., Secades J. Citicoline Preclinical and Clinical Update 2009–2010. Stroke. 2011; 42 [suppl 1]: S36–S39.
  8. Ginsberg M.D. Current Status of Neuroprotection for Cerebral Ischemia. Synoptic Overview. Stroke 2009; 40; S111–S114.
  9. Kennedy E.P. The synthesis of cytidine diphosphate choline, cytidine diphosphate ethanolamine, and related compounds. J Biol Chem 1956; 222: 185–191.
  10. Leciñana L.A.S., Gutirrez M., Roda J.M. et al. Effect of combined therapy with thrombolysis and citicoline in a rat model of embolic stroke. J Clin Neurosci 2006; 247: 121–129.
  11. Miles K.A., Eastwood J.D., Konig M. (eds). Multidetector computed tomography in cerebrovascular disease. CT perfusion imaging. Informa UK, 2007.
  12. O’Collins V.E., Macleod M.R., Donnan G.A. et al. 1026 experimental treatments in acute stroke. Ann Neurol 2006; 59: 467–477.
  13. Ovbiagele B., Kidwell C.S., Starkman S., Saver J.L. Neuroprotective agents for the treatment of acute ischemic stroke. Curr Neurol Neurosci Rep 2003; 3: 9–20.
  14. Rao A.M., Hatcher J.F., Dempsey R.J. Does CDP-choline modulate phospholipase activities after transient forebrain ischemia? Brain Res 2001; 893: 268–272.
  15. Sahota P., Savitz S.I. Investigational therapies for ischemic stroke: neuroprotection and neurorecovery. Neurotherapeutics. 2011 Jul; 8 (3): 434–51.
  16. Saver J.L., Wilterdink J. Choline precursors in acute and subacute human stroke: a meta-analysis. Stroke 2002; 33: 353.
  17. Secades J.J. Citicoline: pharmacological and clinical review, 2010 update. Rev Neurol. 2011 Mar 14; 52 Suppl 2: S1–S62.

Supplementary files

Supplementary Files

Copyright (c) 2012 Piradov M.A., Sergeev D.V., Krotenkova M.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-83204 от 12.05.2022.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies